Premium
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri‐procedural/bleeding management
Author(s) -
Tran H.,
Joseph J.,
Young L.,
McRae S.,
Curnow J.,
Nandurkar H.,
Wood P.,
McLintock C.
Publication year - 2014
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12448
Subject(s) - medicine , perioperative , intensive care medicine , rivaroxaban , warfarin , medical prescription , atrial fibrillation , dabigatran , anticoagulant , surgery , pharmacology
New oral anticoagulants ( NOAC ) are becoming available as alternatives to warfarin to prevent systemic embolism in patients with non‐valvular atrial fibrillation and for the treatment and prevention of venous thromboembolism. An in‐depth understanding of their pharmacology is invaluable for appropriate prescription and optimal management of patients receiving these drugs should unexpected complications (such as bleeding) occur, or the patient requires urgent surgery. The Australasian S ociety of T hrombosis and H aemostasis has set out to inform physicians on the use of the different NOAC based on current available evidence focusing on: (i) selection of the most suitable patient groups to receive NOAC , (ii) laboratory measurements of NOAC in appropriate circumstances and (iii) management of patients taking NOAC in the perioperative period, and strategies to manage bleeding complications or ‘reverse’ the anticoagulant effects for urgent invasive procedures.